Literature DB >> 17600364

Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases.

Mario-Ubaldo Manto1, Marie-Aline Laute, Michèle Aguera, Véronique Rogemond, Massimo Pandolfo, Jérome Honnorat.   

Abstract

OBJECTIVE: Glutamic acid decarboxylase (GAD) catalyzes the conversion of glutamic acid into GABA. GAD autoantibodies (GAD-Ab) have been described in diabetes mellitus and in diseases involving the central nervous system such as stiff-person syndrome and cerebellar ataxia. However, the pathogenic role of GAD-Ab in neurological diseases remains a matter of debate.
METHODS: Using neurophysiological and neurochemical methods, we analyzed the effects of intracerebellar and paraspinal administration of GAD-Ab in rats.
RESULTS: Intracerebellar administration of IgG from patients with GAD-Ab and neurological involvement (IgG-GAD) blocked the potentiation of the corticomotor response normally associated with trains of repetitive peripheral nerve stimulation. When injected in the lumbar paraspinal region, IgG-GAD induced continuous motor activity with repetitive discharges, abnormal exteroceptive reflexes, and increased excitability of anterior horn neurons, as assessed by F/M ratios. Furthermore, IgG-GAD significantly reduced the N-methyl-D-aspartate-mediated production of nitric oxide in cerebellar nuclei and impaired the synaptic regulation of glutamate after N-methyl-D-aspartate administration. These effects were not observed after administration of IgG from the following groups: (1) patients with GAD-Ab, diabetes mellitus, and without neurological complications; and (2) control patients.
INTERPRETATION: These results indicate that stiff-person syndrome and cerebellar ataxia are the direct consequence of antibody-mediated neuronal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600364     DOI: 10.1002/ana.21123

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  60 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 2.  Infections, inflammation and epilepsy.

Authors:  Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher
Journal:  Acta Neuropathol       Date:  2015-09-30       Impact factor: 17.088

Review 3.  Diabetes and epilepsy in children and adolescents.

Authors:  M Loredana Marcovecchio; Marianna Immacolata Petrosino; Francesco Chiarelli
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

Review 4.  [Autoimmune synaptic encephalopathies].

Authors:  M A Friese; T Magnus
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

Review 5.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

6.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

Review 7.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

8.  New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin.

Authors:  Michael Marnane; Aangela Vincent; Michael Hutchinson
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

9.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

10.  Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.

Authors:  Vincent Planche; Ana Marques; Miguel Ulla; Marc Ruivard; Franck Durif
Journal:  Cerebellum       Date:  2014-06       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.